/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

A

Astrid Kiermaier

Roche (Switzerland)(CH)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

50

Papers

3.2K

Citations

18

h-index

24

i10-index

Astrid Kiermaier is an academic researcher from Roche (Switzerland). The author has contributed to research in topics: HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 18, co-authored 43 publications.

Research Topics

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Monoclonal and Polyclonal Antibodies Research Cancer Immunotherapy and Biomarkers Advanced Breast Cancer Therapies

Papers by this author

works

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

2014 · Gastric Cancer · 592 citations

https://doi.org/10.1007/s10120-014-0402-y

Eric Van Cutsem Yung‐Jue Bang Feng-yi Feng Jian Xu

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

2014 · Journal of Clinical Oncology · 367 citations

https://doi.org/10.1200/jco.2013.54.5384

José Baselga Javier Cortés Seock‐Ah Im Emma Clark

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

2017 · Annals of Oncology · 237 citations

https://doi.org/10.1093/annonc/mdx773

Sandra M. Swain Michael S. Ewer Giuseppe Viale Suzette Delaloge

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy

2018 · JNCI Journal of the National Cancer Institute · 89 citations

https://doi.org/10.1093/jnci/djy076

Michail Ignatiadis Gert Van den Eynden Roberto Salgado Marco Fornili

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial

2022 · Gastric Cancer · 51 citations

https://doi.org/10.1007/s10120-022-01335-4

Josep Tabernero Paulo M. Hoff Lin Shen Atsushi Ohtsu

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

2022 · European Journal of Cancer · 17 citations

https://doi.org/10.1016/j.ejca.2022.01.031

Richard D. Gelber Xin V. Wang Bernard F. Cole David Cameron

Research topics

topics

HER2/EGFR in Cancer Research

Breast Cancer Treatment Studies

Monoclonal and Polyclonal Antibodies Research

Cancer Immunotherapy and Biomarkers

Advanced Breast Cancer Therapies

Chat about Author

Papers

Chat

Click to start Chat